Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Details
Serval ID
serval:BIB_9E4B633524A8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Journal
JAMA network open
Working group(s)
AMYPAD consortium
Contributor(s)
Abdelnour C., Aguilera N., Aksman L., Alarcón-Martín E., Alegret M., Alonso-Lana S., Altomare D., Andersen P., Arab M., Aspö M., Bader I., Bader I., Banton N., Barkhof F., Barnes R., Barrie D., Battle M., Belén Collado A., Bellet J., Berkhof J., Biger M., Birck C., Bischof G., Boada M., Boellaard R., Bogdanovic N., Bollack A., Bombois S., Borg S., Borjesson-Hanson A., Boskov V., Boutantin J., Boutoleau-Bretonniere C., Bouwman F., Breuilh L., Bringman E., Brunel B., Bucci M., Buckley C., Buendía M., Bullich S., Calvet A., Cañada L., Cañada M., Caprioglio C., Cardoso J., Carlier J., Carre E., Carrie I., Cassagnaud P., Cassol E., Castilla-Martí M., Cazalon E., Chaarriau T., Chaigeau R., Chalmers T., Clerc M.T., Clerigue M., Cognat E., Coll N., Collij L.E., Connely P., Cordier E., Costes C., Coulange C., Courtemanche H., Creisson E., Crinquette C., Cuevas R., Cufi M.N., Dardenne S., de Arriba M., de Costa Luis C., de Gier Y., de Verbizier Lonjon D., Dekker V., Dekyndt B., Delbeuck X., Delrieu J., Demonet J.F., Deramecourt V., Desclaux F., Diaz C., Diego S., Djafar M., Dölle B., Doull L., Dricot L., Drzezga A., Dubois B., Dumont J., Dumur J., Dumurgier J., Dvorak M., Ecay M., Edison P., Escher C., Estanga A., Esteban E., Fanjaud G., Farrar G., Fauria K., Felez Sanchez M., Feukam Talla P., Ford L., Frisoni G.B., Fuster D., Gabelle A., Garibotto V., Gaubert S., Gauci C., Geldhof C., Georges J., Ghika J., Gismondi R., Gispert J.D., González E., Goovaerts V., Goulart D.M., Grasselli C., Grau-Rivera O., Gray K., Greensmith M., Grozn L., Guillemaud C., Gunn F., Guntur Ramkumar P., Hagman G., Hansseuw B., Heeman F., Hendriks J., Himmelmann J., Hitzel A., Hives F., Hoenig M., Hourrègue C., Hudson J., Huguet J., Ibarria M., Iidow I., Indart S., Ingala S., Ivanoiu A., Jacquemont C., Jelic V., Jessen F., Jiao J., Jofresa S., Jonsson C., Kaliukhovich D., Kern S., Kivipelto M., Knezevic I., Kuchcinski G., Laforce M., Lafuente A., Lala F., Lammertsma A., Lax M., Lebouvier T., Lee H.Y., Lee L., Leeuwis A., Lefort A., Legrand J.F., Leroy M., Lesoil Markowski C., Levy M., Lhommel R., Lopes R., Lopes Alves I., Lorenzini L., Lorette A., Luckett E., Lundin M., Mackowiak M.A., Malotaux V., Manber R., Manyakov N., Markiewicz P., Marne P., Marquié M., Martín E., Martínez J., Martinez Lage P., Mastenbroek S.E., Maureille A., Meersmans K., Mett A., Milne J., Minguillón C., Modat M., Molinuevo J.L., Montrreal L., Moro C., Müller T., Muniz G., Mutsarts H.J., Nilsson T., Ninerola A., Nordberg A., Novaes W., Nuno Carmelo Pires Silva J., Operto G., Orellana A., Ousset P.J., Outteryck O., Pallardy A., Palombit A., Pancho A., Pappon M., Paquet C., Pariente J., Pasquier F., Payoux P., Peaker H., Pelejà E., Pennetier D., Pérez-Cordón A., Perissinotti A., Perrenoud M.P., Petit S., Petyt G., Pfeil J., Pirotte B., Pla S., Plaza Wuthrich S., Poitrine L., Pollet M., Poncelet J.B., Prior J., Pruvo J.P., Putallaz P., Queneau M., Quenon L., Rădoi A., Rafiq M., Ramage F., Ramis M., Reinwald M., Rios G., Ritchie C., Rodriguez E., Rollin A., Rouaud O., Sacuiu S., Saint-Aubert L., Sala A., Salabert A.S., Saldias J., Salvadó G., Sanabria A., Sannemann L., Sastre N., Savina D., Savitcheva I., Schaeverbeke J., Scheltens P., Schildermans C., Schmidt M., Schöll M., Schuermans J., Semah F., Shekari M., Skoog I., Sotolongo-Grau O., Stephens A., Stewart T., Stutzmann J., Tait M., Tárraga L., Tartari J.P., Tysen-Backstrom A.C., Valero S., Vallez Garcia D., van Berckel BNM, van Essen M., Van Laere K., van Leur J., van Maurik I.S., Vandenberghe R., Vellas B., Virolinen J., Visser P.J., Walker Z., Walles H., Wallin E., Whitelaw G., Wimberley C., Win Z., Wink A.M., Wolz R., Woodside J., Yaqub M., Zettergren A., Zeyen P.
ISSN
2574-3805 (Electronic)
ISSN-L
2574-3805
Publication state
Published
Issued date
03/01/2023
Peer-reviewed
Oui
Volume
6
Number
1
Pages
e2250921
Language
english
Notes
Publication types: Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Abstract
Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know their amyloid status; however, the disclosure of a positive amyloid-PET result might have psychological risks.
To assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive.
This prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022.
Disclosure of amyloid-PET result.
Psychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale-Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms).
After disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30]) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2]; P < .001), IES-R avoidance (0.00 [0.00 to 0.69] vs 0.00 [0.00 to 0.00]; P < .001), IES-R intrusions (0.50 [0.13 to 0.75] vs 0.00 [0.00 to 0.25]; P < .001), and IES-R hyperarousal (0.33 [0.00 to 0.67] vs 0.00 [0.00 to 0.00]; P < .001) scores than the 78 patients who were amyloid-negative (median [IQR], age, 67 [64 to 74] years, 45 men [58%], median [IQR] education: 15 [12 to 17] years, median [IQR] MMSE score: 29 [28 to 30]). There were no observed differences between amyloid-positive and amyloid-negative patients in the median (IQR) HADS Anxiety (-1.0 [-3.0 to 1.8] vs -2.0 [-4.8 to 1.0]; P = .06) and Depression (-1.0 [-2.0 to 0.0] vs -1.0 [-3.0 to 0.0]; P = .46) deltas (score after disclosure - scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = -0.43; P = .02) whereas the presence of study partner was associated with higher disclosure-related distress (W = 7.5; P = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up.
The disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern.
To assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive.
This prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022.
Disclosure of amyloid-PET result.
Psychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale-Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms).
After disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30]) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2]; P < .001), IES-R avoidance (0.00 [0.00 to 0.69] vs 0.00 [0.00 to 0.00]; P < .001), IES-R intrusions (0.50 [0.13 to 0.75] vs 0.00 [0.00 to 0.25]; P < .001), and IES-R hyperarousal (0.33 [0.00 to 0.67] vs 0.00 [0.00 to 0.00]; P < .001) scores than the 78 patients who were amyloid-negative (median [IQR], age, 67 [64 to 74] years, 45 men [58%], median [IQR] education: 15 [12 to 17] years, median [IQR] MMSE score: 29 [28 to 30]). There were no observed differences between amyloid-positive and amyloid-negative patients in the median (IQR) HADS Anxiety (-1.0 [-3.0 to 1.8] vs -2.0 [-4.8 to 1.0]; P = .06) and Depression (-1.0 [-2.0 to 0.0] vs -1.0 [-3.0 to 0.0]; P = .46) deltas (score after disclosure - scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = -0.43; P = .02) whereas the presence of study partner was associated with higher disclosure-related distress (W = 7.5; P = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up.
The disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern.
Keywords
Male, Humans, Adult, Aged, Alzheimer Disease/diagnosis, Brain/metabolism, Amyloid beta-Peptides/metabolism, Prospective Studies, Disclosure, Positron-Emission Tomography, Cognitive Dysfunction/diagnostic imaging
Pubmed
Web of science
Open Access
Yes
Create date
23/01/2023 12:16
Last modification date
24/10/2023 7:11
Usage data
